Table 4

Differential expression of putative tumor oncogenes and suppressor genes in melanoma

    Oncogenes


    Gene

    Fold Increase

    Interval of Increase

    Activating Mechanisms in other Tumor Histologies

    Affected Tumor Types


SPP-1

13.2

Thin to IM

C-Met activation via αvβ3 receptor; Inhibition of apoptosis

Breast, HCC, Prostate, CRC, Head & Neck

MITF

3.7

Progressive increase

Somatic alteration via gene amplification (Chr.#3p13-3p14)

None, Lineage Specific for Melanoma

CITED-1 (cbp/p300 transactivator)

12.4

IM to Thick

Activation of Stat-3, Ras/MAPK kinase signaling via Ets1, Ets2

Thyroid

GDF15 (PLAB)

22.7

IM to Thick

Lineage specific activation or repression of ERK1/2; Integrator of AKT pathway

Breast, CRC, Gastric, Prostate, Pancreatic

c-Met

14.5

Thick to Met

Ras-Associated Protein (Rap1)/ERK/MAPK, rac1, Grb2, PI3K, src activation

CRC, Breast, Ovarian, Pancreatic, Liver

HOX Locus (A3, A10, B6, B7, B13)

2.1 – 5.0

Progressive increase

Downstream activation of WT-1, NFKB, NR4A3, BCL2, p53

AML, Breast, SCLC


    Tumor Suppressor Genes


    Gene

    Fold Decrease

    Interval of Decrease

    Suppressor Mechanisms in other Tumors Histologies

    Affected Tumor Types


PITX-1

13.9

Thin to IM

Ras Pathway (RASAL1)

Barrett's [Esophagus] Prostate, Bladder

CST6 (CST E/M)

66.7

IM to Thick

Hypermethylation

Breast, Glioma

PDGFRL

7.3

IM to Thick

Gene Deletion from Chr.# 8p21.3-p22

HCC, CRC, NSCLC

DSC3

42.8

Progressive decrease

Hypermethylation

Breast

POU2F3

49

Thin to IM

Hypermethylation

Cervical

CLCA2

162

MIS/Thin to MM

Hypermethylation

Breast


Note: Tables represent a partial list of identified tumor oncogenes and tumor suppressor genes (TSG's) in PCM and MM samples. The fold increase represents the greatest fold change noted throughout all comparisons of each PCM tumor thickness to MM. The activating/suppressive mechanism and affected tumor type are also identified. Abbreviations: HCC, hepatocellular carcinoma, CRC, colorectal carcinoma, NSCLC, non-small cell lung cancer, SCLC, squamous cell lung cancer, AML, acute myelogenous leukemia.

Riker et al. BMC Medical Genomics 2008 1:13   doi:10.1186/1755-8794-1-13

Open Data